AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
Launched by SHANGHAI ZHONGSHAN HOSPITAL · Dec 23, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help doctors better screen and diagnose heart conditions called cardiomyopathies using a special imaging test known as coronary computed tomography angiography (CCTA). Cardiomyopathies are diseases of the heart muscle that can affect how well the heart pumps blood. The goal of the study is to create a computer program that can analyze CCTA images and assist healthcare providers in making more accurate diagnoses for patients suspected of having these heart conditions.
To participate in the trial, individuals must have a confirmed diagnosis of a cardiomyopathy or related heart disease and should have undergone at least one CCTA before any surgical or device treatments. People who have other types of heart problems or who have already had certain heart procedures may not be eligible. This study is still in the planning stages and is not yet recruiting participants. If you qualify and join the study, you can expect to contribute to developing a new tool that could help improve heart disease diagnosis and potentially benefit many patients in the future.
Gender
ALL
Eligibility criteria
- Cardiomyopathy cohort:
- * Inclusion Criteria:
- • 1. A clinical diagnosis of cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, cardiac amyloidosis, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and coronary artery disease/ischemic heart disease.
- • 2. At least one CCTA before surgery or implantable device treatment.
- * Exclusion Criteria:
- • 1. No recorded diagnosis of cardiomyopathy or undetermined type of cardiomyopathy.
- • 2. A clinical diagnosis of secondary cardiac abnormalities due to other organic or systemic diseases.
- • 3. Surgery or implantable device treatment before CCTA examination.
- Control cohort:
- • Inclusion Criteria: participants with at least one CCTA examination.
- • Exclusion Criteria: clinical diagnosis of cardiovascular diseases (including cardiomyopathy, history of myocardial infarction, history of cardiac surgery, stent implantation, ICD implantation and so on) or secondary cardiac abnormalities due to systemic diseases.
About Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Chenguang Li, MD, PhD
Principal Investigator
Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported